Developing new antibodies to eliminate HIV-1 from the body
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir
This study is working on developing special antibodies that can help fight HIV-1 by targeting it in multiple ways, and it's testing these antibodies in mice to see if they can clear hidden virus spots in the body, which could lead to better treatments for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10515649 on NIH RePORTER |
What this research studies
This research focuses on creating broadly neutralizing antibodies (bNAbs) that can effectively target and eliminate HIV-1 from the body. By engineering these antibodies to bind to multiple sites on the virus, the study aims to enhance their ability to neutralize the virus and prevent it from spreading. The approach involves using humanized mouse models to test the efficacy of these antibodies in clearing HIV-1 reservoirs, which are the hidden pockets of the virus that can cause rebound infections. Patients may benefit from advancements in treatment strategies that could lead to a functional cure for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not responded adequately to current antiretroviral therapies.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively clear HIV-1 from the body, potentially offering a functional cure for patients living with HIV.
How similar studies have performed: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, but this specific approach of combining multiple antibodies is relatively novel.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Li, Yuxing — University of Maryland Baltimore
- Study coordinator: Li, Yuxing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.